Profile data is unavailable for this security.
About the company
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
- Revenue in USD (TTM)2.12bn
- Net income in USD-309.19m
- Incorporated2007
- Employees4.42k
- LocationNatera Inc13011 MCCALLEN PASSBUILDING A SUITE 100AUSTIN 78753United StatesUSA
- Phone+1 (650) 249-9090
- Fax+1 (302) 674-5266
- Websitehttps://www.natera.com/
Mergers & acquisitions
| Acquired company | NTRA:NSQ since announced | Transaction value |
|---|---|---|
| Foresight Diagnostics Inc | -12.54% | 465.12m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Universal Health Services Inc | 16.99bn | 1.38bn | 14.67bn | 86.00k | 11.16 | 2.05 | 7.33 | 0.8634 | 21.04 | 21.04 | 259.66 | 114.75 | 1.14 | -- | 7.08 | 197,587.30 | 9.43 | 6.68 | 11.52 | 7.94 | -- | -- | 8.24 | 6.62 | 0.9595 | 12.35 | 0.3913 | 5.63 | 10.82 | 6.82 | 59.17 | 7.04 | 7.56 | 5.92 |
| Centene Corp | 194.78bn | -6.68bn | 19.96bn | 61.10k | -- | 1.00 | -- | 0.1025 | -13.63 | -13.62 | 394.60 | 40.57 | 2.45 | -- | 10.30 | 3,187,840.00 | -8.39 | 0.4683 | -15.18 | 0.771 | 7.12 | 10.08 | -3.43 | 0.2365 | -- | -0.4145 | 0.4646 | -- | 19.44 | 11.88 | -302.06 | -- | -2.47 | -- |
| Tenet Healthcare Corp | 21.31bn | 1.41bn | 20.31bn | 74.48k | 14.92 | 4.81 | 6.29 | 0.9531 | 15.49 | 15.49 | 234.60 | 48.02 | 0.7271 | 10.89 | 8.06 | -- | 8.08 | 7.28 | 11.63 | 10.40 | 82.26 | 82.59 | 11.11 | 10.10 | 1.68 | 6.61 | 0.5948 | -- | 3.12 | 3.85 | -56.03 | 28.67 | 13.34 | -- |
| Humana Inc | 129.66bn | 1.19bn | 22.20bn | 65.68k | 18.77 | 1.26 | 10.43 | 0.1712 | 9.81 | 9.81 | 1,074.55 | 146.42 | 2.72 | -- | -- | -- | 2.74 | 4.86 | -- | -- | -- | -- | 1.01 | 2.05 | -- | 4.79 | 0.4109 | 19.21 | 10.11 | 10.94 | -1.57 | -18.81 | -10.75 | 3.02 |
| Quest Diagnostics Inc | 11.04bn | 988.00m | 22.76bn | 57.00k | 23.61 | 3.17 | 14.46 | 2.06 | 8.76 | 8.76 | 97.87 | 65.18 | 0.6816 | 39.03 | 8.14 | 193,596.50 | 6.20 | 8.03 | 7.25 | 9.31 | 33.32 | 34.94 | 9.10 | 11.33 | 0.9609 | 6.53 | 0.4377 | 29.29 | 11.78 | 3.18 | 14.09 | -7.06 | 4.74 | 7.68 |
| Labcorp Holdings Inc | 13.77bn | 855.20m | 23.43bn | 70.00k | 27.75 | 2.70 | 15.26 | 1.70 | 10.18 | 10.18 | 163.87 | 104.78 | 0.7466 | 19.61 | 6.13 | 196,647.10 | 4.64 | 6.16 | 5.56 | 7.33 | 28.45 | 32.18 | 6.22 | 9.17 | 1.35 | 5.51 | 0.3934 | -- | 6.97 | 2.40 | 96.73 | -1.96 | 4.13 | -- |
| Natera Inc | 2.12bn | -309.19m | 28.70bn | 4.42k | -- | 22.65 | -- | 13.56 | -2.28 | -2.28 | 15.69 | 9.10 | 1.24 | 13.57 | 7.14 | 478,452.50 | -18.12 | -30.60 | -23.17 | -38.82 | 63.66 | 51.43 | -14.61 | -40.61 | 3.13 | -- | 0.0603 | -- | 56.75 | 41.20 | 56.20 | -- | 72.97 | -- |
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 11.82m | 8.55% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.27m | 8.15% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2025 | 10.47m | 7.57% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 7.09m | 5.12% |
| Farallon Capital Management LLCas of 30 Sep 2025 | 4.25m | 3.08% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.23m | 2.33% |
| Duquesne Family Office LLCas of 30 Sep 2025 | 3.21m | 2.32% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.61m | 1.89% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 2.53m | 1.83% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 2.45m | 1.77% |
